<DOC>
<DOCNO>EP-0624160</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2-ISOCEPHEM AND OXACEPHEM DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIAL AGENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3154	A61K3154	A61K315383	C07D50706	C07D50704	A61P3104	C07D51304	C07D40500	A61K31542	C07D51300	A61P3100	C07D50708	C07D49804	A61K31535	C07D50702	A61K315375	C07D40506	A61K31535	C07D50700	A61K31542	C07D49800	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	C07D	C07D	A61P	C07D	C07D	A61K	C07D	A61P	C07D	C07D	A61K	C07D	A61K	C07D	A61K	C07D	A61K	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	C07D507	C07D507	A61P31	C07D513	C07D405	A61K31	C07D513	A61P31	C07D507	C07D498	A61K31	C07D507	A61K31	C07D405	A61K31	C07D507	A61K31	C07D498	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I) or salts thereof wherein R
<
1
>
 is hydrogen, methoxy or formamido; R
<
2
>
 is an acyl group; CO2R
<
3
>
 is a carboxy group or a carboxylate anion, or R
<
3
>
 is a carboxy protecting group, pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R
<
4
>
 represents hydrogen or up to four substituents; X is O, S, SO or SO2; Y is O, S, SO or SO2; n is 0 or 1; and m is 1 or 2. The compounds have antibacterial activity. Methods or synthesis of, and pharmaceutical formulations containing, compounds (I) are also described.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention relates to novel Î²-lactam compounds, their preparation and
their use, and in particular to a novel class of 2-isocephems. These
compounds have antibacterial properties, and are therefore of use in the
treatment of bacterial infections in humans and animals caused by a wide
range of organisms.J. Med. Chem. (1988), 31, 1190-1196 discloses 0-2-isocephems of general
formula (A):

wherein Ra, Rb and Rc are various substituents.We have found a particularly advantageous class of 2-isocephems bearing
a cyclic ether or thio-ether substituent at the 3-position of the cephem
nucleus.The present invention provides a compound of formula (I) or a salt thereof:

wherein
R1 is hydrogen, methoxy or formamido; R2 is an acyl group of the formulae (a) - (f):
A2CO-A2-X3-(CH2)p-CO-
wherein p is 0, 1 or 2; m is 0, 1 or 2; A1 is (C1-6) alkyl, substituted (C1-6) alkyl
wherein the substituents are as for R4, (C3-6) cycloalkyl, cyclohexenyl,
cyclohexadienyl, an aryl or heteroaryl group, a (C1-6) alkylthio group, or (C1-6)
alkyloxy; X1 is a hydrogen or halogen atom, a carboxylic acid, carboxylic ester,
sulphonic acid, azido, tetrazolyl, hydroxy, acyloxy, amino, ureido, acylamino,
heterocyclylamino, guanidino or acylureido group; A2 is aryl; 3-arylisoxazolyl; 3-aryl-5-methylisoxazolyl;
a substituted C1-6 alkyl group; or a substituted
dithietane; X2 is a -CH2OCH2-, -CH2SCH2- or alkylene group; X3 is an oxygen
or sulphur atom; A3 is an aryl or heteroaryl group; and A4 is hydrogen, (C1-6)alkyl,
(C3-8) cycloalkyl, (C3-8) cycloalkyl(C1-6)alkyl, (C1-6)alkoxycarbonyl(C1-6)alkyl,
(C2-6) alkenyl, carboxy(C1-6)alkyl, (C2-6) alkynyl, aryl or (C1-6)alkyl
substituted by up to three aryl groups; 
CO2R3 is a carboxy group or a carboxylate anion, or R3 is a readily removable
carboxy protecting group or a pharmaceutically acceptable salt-forming group
or invivo hydrolysable ester group;
R4 represents hydrogen or up to four substituents, which may be present on
any of the carbon atoms in the ring system shown, selected from alkyl, alkenyl,
alkynyl, alkoxy, hydroxy, halogen, amino, alkylamino, acylamino, dialkylamino,
CO2R, CONR2, SO2NR2 where R is hydrogen or alkyl, aryl and heterocyclyl,
which may be the same or different and wherein any R4 alkyl substituent is
optionally substituted by one or more substituents selected from the list from
which R4 is selected; said alkyl, alkenyl, alkyl, acyl and alkoxy groups having
up to 6 carbon atoms;X is O, S, SO or SO2; Y is O, S, SO or SO2; n is 0 or 1; and m is 1 or 2;
"aryl" means phenyl or
</DESCRIPTION>
<CLAIMS>
A compound of formula (I) or a salt thereof:


wherein

R
1
 is hydrogen, methoxy or formamido;
R
2
 is an acyl group of the formulae (a) - (f):

A2CO-
A
2
-X
3
-(CH
2
)
p
-CO-
 
wherein p is 0, 1 or 2; m is 0, 1 or 2; A
1
 is (C
1-6
) alkyl, substituted (C
1-6
) alkyl
wherein the substituents are as for R
4
, (C
3-5
) cycloalkyl, cyclohexenyl,
cyclohexadienyl, an aryl or heteroaryl group, a (C
1-6
) alkylthio group, or (C
1-6
)
alkyloxy; X
1
 is a hydrogen or halogen atom, a carboxylic acid, carboxylic ester,
sulphonic acid, 
azido, tetrazolyl, hydroxy, acyloxy, amino, ureido, acylamino,
heterocyclylamino, guanidino or acylureido group; A
2
 is aryl; 3-arylisoxazolyl; 3-aryl-5-methylisoxazolyl;
a substituted C
1-6
 alkyl group; or a substituted
dithietane; X
2
 is a -CH
2
OCH
2
-, -CH
2
SCH
2
- or alkylene group; X
3
 is an oxygen
or sulphur atom; A
3
 is an aryl or heteroaryl group; and A
4
 is hydrogen, (C
1
-
6
)alkyl,
(C
3-8
) cycloalkyl, (C
3-8
) cycloalkyl(C
1-6
)alkyl, (C
1-6
)alkoxycarbonyl(C
1
-
6
)alkyl,
(C
2-6
) alkenyl, carboxy(C
1-6
)alkyl, (C
2-6
) alkynyl, aryl or (C
1-6
)alkyl
substituted by up to three aryl groups;
CO
2
R
3
 is a carboxy group or a carboxylate anion, or R
3
 is a readily removable
carboxy protecting group or a pharmaceutically acceptable salt-forming group

or 
in
vivo
 hydrolysable ester group;
R
4
 represents hydrogen or up to four subsfituents, which may be present on
any of the carbon atoms in the ring system shown, selected from alkyl, alkenyl,

alkynyl, alkoxy, hydroxy, halogen, amino, alkylamino, acylamino, dialkylamino.
CO
2
R, CONR
2
, SO
2
NR
2
 where R is hydrogen or alkyl, aryl and heterocyclyl,
which may be the same or different and wherein any R
4
 alkyl substituent is
optionally substituted by one or more substituents selected from the list from

which R
4
 is selected; said alkyl, alkenyl, alkynyl, acyl, and alkoxy groups having
up to 6 carbon atoms;
X is O, S, SO or SO
2
; Y is O, S, SO or SO
2
; n is 0 or 1; and m is 1 or 2,
"aryl" means phenyl or naphthyl, each optionally substituted with up to five

groups selected from halogen, mercapto, (C
1-6
) alkyl, phenyl, (C
1-6
) alkoxy,
hydroxy(C
1-6
)alkyl, mercapto(C
1-6
)alkyl, halo(C
1-6
) alkyl, hydroxy, amino, nitro,
carboxy, (C
1-6
) alkylcarbonyloxy, (C
1-6
)alkoxycarbonyl, formyl, and (C
1
-
6
)alkylcarbonyl
groups; "heterocyclyl" means aromatic or non-aromatic, single

or fused, rings containing up to four hetero-atoms in each ring selected from 
oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted

by up to three groups selected from halogen, (C
1-6
)alkyl, (C
1-6
) alkoxy,
halo(C
1-6
)alkyl, hydroxy, carboxy, carboxy salts, (C
1-6
)alkoxycarbonyl,
(C
1-6
)alkoxycarbonyl(C
1-6
)alkyl, aryl, and oxo groups; and "heteroaryl" means a
heteroaromatic heterocyclic ring or ring system, having 5 or 6 ring atoms in

each ring.
A compound according to claim 1 being a compound of formula (Ia) or
pharmaceutically acceptable salts or pharmaceutically acceptable 
in
vivo

hydrolysable esters thereof:


wherein R
1
, R
2
, R
4
, m, n, X and Y are as defined with respect to formula
(I) and the group CO
2
R
6
 is CO
2
R
3
 where CO
2
R
3
 is a carboxy group or a
carboxylate anion.
A compound according to claim 1 wherein X is O or S.and/or Y is O or S.
A compound according to claim 1 wherein R
1
 is hydrogen.
A compound according to claim 1 wherein the cyclic ether or thio-ether
at the 3-position of the cephalosporin nucleus is unsubstituted.
A compound according to claim 1 wherein m is 1.
A compound according to clam 6 wherein the cyclic ether at the 3-position
of the cephalosporin nucleus is a tetrahydrofuran-2-yl group.
A compound according to claim 1 wherein n is 0.
A compound according to claim 1 wherein the acyl group R2 is a group:

A
3
-C(=N~OA
4
)CO-
 
in which A
3
 is 2-aminothiazol-4-yl and A
4
 is selected from hydrogen,
methyl, ethyl, cyclopropylmethyl, triphenylmethyl (trityl), cyclobutyl,

cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, carboxymethyl,
carboxypropyl and 
t
-butoxycarbonylmethyl.
A compound according to claim 9 wherein A
4
 is methyl or hydrogen.
A compound according to claim 1, being:

Sodium (6
S
,7
S
)-7-[2-(2-Aminothiazol-4-yl)-2-(Z)-methoxyiminoacetamido]-3-[(S)-(tetrahydrofuran-2-yl]
isoceph-3-em-4-carboxylate,
or
Sodium (6
S
,7
S
)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-methoxyiminoacetamido]-8-oxo-3-(tetrahydrofuran-2-yl)-aza-4-oxabicyclo[4.2.0]
oct-2-ene-2-carboxylate
A process for the preparation of a compound of formula (I) as defined in
claim 1, which process comprises treating a compound of formula (II) or a salt

thereof:


wherein R
1
, CO
2
R
3
, R
4
, m, n, X and Y are as defined in claim 1, wherein any
reactive groups may be protected, and wherein the amino group is optionally

substituted with a group which permits acylation to take place; with an acid of
formula (III) or a N-acylating derivative thereof:


R
2
OH

wherein R
2
 is the acyl group as defined with respect to formula (I) and
wherein any reactive groups may be protected; and thereafter, if necessary

or desired, carrying out one or more of the following steps:

i) removing any protecting groups; 
ii) converting the group CO
2
R
3
 into a different group CO
2
R
3
;
iii) converting the group R
2
 into a different group R
2
;
iv) converting the group X into a different group X, for example X into
SO or SO
2
;
v) converting the group Y into a different group Y, for example S into
SO or SO
2
;
vi) converting the product into a salt or ester.
A compound of formula (II) as defined in claim 12.
A process for the preparation of a compound of formula (I) or (Ia) as
defined in claim 1 or 2 and wherein X is S, SO or SO
2
 comprising the step of
cyclising a compound of formula (IX):



wherein Y, R
1
, R
4
, and m, n, and CO
2
R
3
 are as defined in claim 1; each R
x
 may
be the same or different and is independently selected from (C
1-6
) alkyl or aryl,
and R
21
 is a group R
2
 as defined in claim 1 or is an amino-protecting group or is
a group which permits acylation to take place, and thereafter if necessary or

desired, carrying out one or more of the following steps:

i) removing any protecting groups;
ii) converting the group CO
2
R
3
 into a different group CO
2
R
3
;
iii) converting the group R
21
 into a different group R
21
; 
iv) converting the group Y into a different group Y;
v) converting the product into a salt.
A compound of formula (IX) as defined in claim 14.
A compound of formula (VIII):


wherein Y, R
1
, R
4,
 R
21
, m n, and CO
2
R
3
 are as defined in claim 14
A compound of formula (VI):


wherein R
3
, R
4
, R
21
, Y and m and n are as defined in claim 14 and R
9
 is a hydroxy-protecting
group.
A process for the preparation of a compound of formula (I) and (II) in which X is
0 comprising cyclising a compound of formula (VIII) as defined in claim 16 then

thereafter if necessary or desired, carrying out one or more of the following steps: 

i) removing any protecting groups;
ii) converting the group CO
2
R
3
 into a different group CO
2
R
3
;
iii) converting the group R
21
 into a different group R
21
;
iv) converting the group Y into a different group Y;
v) converting the product into a salt.
A pharmaceutical composition comprising a compound of the formula (Ia), as
defined in claim 2, or a pharmaceutically acceptable salt or 
in vivo
 hydrolysable ester
thereof and a pharmaceutically acceptable carrier.
A compound of the formula (Ia), as defined in claim 2, or a pharmaceutically
acceptable salt or 
in vivo
 hydrolysable ester thereof, for use as a therapeutic agent, and
in particular, an 
in vivo
 hydrolysable ester thereof for use as an orally administrable
therapeutic agent.
A compound of the formula (Ia), as defined in claim 2, or a pharmaceutically
acceptable salt or 
in vivo
 hydrolysable ester thereof, for use in the treatment of bacterial
infections, more particularly an 
in vivo
 hydrolysable ester thereof, for use in the oral
treatment of bacterial infections.
The use of a compound of the formula (Ia), as defined in claim 2, or a
pharmaceutically acceptable salt or 
in vivo
 hydrolysable ester thereof, for the
manufacture of a medicament for the oral treatment of bacterial infections.
</CLAIMS>
</TEXT>
</DOC>
